ArticleBMJ health & care informatics2025
Artificial intelligence for predicting interstitial fibrosis and tubular atrophy using diagnostic ultrasound imaging and biomarkers.
Article in BMJ health & care informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Applications of Machine Learning for Early Diagnosis and Prognosis of Chronic Kidney Disease: Current Evidence.Diagnostics (Basel, Switzerland) · 2026Review
- Advancements in the non-invasive diagnosis of renal fibrosis.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a global health concern characterised by irreversible renal damage that is often assessed using invasive renal biopsy. Accurate evaluation of interstitial fibrosis and tubular atrophy (IFTA) is crucial for CKD management. This study aimed to leverage machine learning (ML) models to predict IFTA using a combination of ultrasonography (US) images and patient biomarkers.
methodsWe retrospectively collected US images and biomarkers from 632 patients with CKD across three hospitals. The data were subjected to pre-processing, exclusion of sub-optimal images, and feature extraction using a dual-path convolutional neural network. Various ML models, including XGBoost, random forest and logistic regression, were trained and validated using fivefold cross-validation.
resultsThe dataset was divided into training and test datasets. For image-level IFTA classification, the best performance was achieved by combining US image features and patient biomarkers, with logistic regression yielding an area under the receiver operating characteristic curve (AUROC) of 99%. At the patient level, logistic regression combining US image features and biomarkers provided an AUROC of 96%. Models trained solely on US image features or biomarkers also exhibited high performance, with AUROC exceeding 80%.
conclusionOur artificial intelligence-based approach to IFTA classification demonstrated high accuracy and AUROC across various ML models. By leveraging patient biomarkers alone, this method offers a non-invasive and robust tool for early CKD assessment, demonstrating that biomarkers alone may suffice for accurate predictions without the added complexity of image-derived features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.